Home > About IBA Lifesciences

About us:

Company Profile

IBA GmbH – Solutions for Life Sciences

For more than two decades IBA provides innovative technologies for life science applications. The product portfolio includes tools for cell selection & expansion, protein production & assays as well as custom oligos & predefined DNA/RNA.

Cell selection & expansion

Automated cell selection via the Fab-TACS® technology directly from whole blood is possible using IBA’s design award winning FABian® device. Customized protocols depending on the cell type, the sample volume and the intended yield for the cell type of interest allow a convenient fully automatic cell isolation. Strep-tagged Fab fragments (Fab-Streps®) reversibly capture and release the target cells during the selection process. This delivers label-free, non-activated target cells in a standardized manner of highly reproducible quality. Isolated cells are suitable for all further immunologic or cell biologic investigations including cell based diagnostics or assays, e.g. pharmacological analysis of drug levels in the isolated cell fraction. Alternatively to FABian® we offer gravity flow columns for manual cells selection based on the same technology. For T cell stimulation, we offer completely novel reversible reagents, the Streptamers® for cell expansion, which provide unique flexibility for cell research.

Protein production & assays

The Strep-tag® technology is IBA's proprietary and versatile protein purification, detection and immobilization platform. It is one of the most widely used systems for affinity purification that provides exceptional pure proteins. Recently the third generation of the Strep-tag system was launched based on the new Strep-Tactin®XT and Twin-Strep-tag®. Strep-Tactin®XT is a further developed Strep-Tactin® with extra tight binding to Twin-Strep-tag® now enabling the usage of the Strep-tag® technology in applications where extra tight binding is a requirement. Thereby the third generation Strep-tag® technology now enters the field of assay development and screening. This opens new possibilities in the pharmaceutical and biotech sector for, e.g. screening of new diagnostic targets and the development of diagnostic assays.

IBA Team

Dr. Mike Rothe

CEO - Dr. Mike Rothe
Managing Director, Chief Executive Officer
Mike Rothe has extensive biotech industry experience and expertise in building successful life science companies. His involvement in biotechnology started as a visiting scientist at Genentech, Inc. (South San Francisco, USA) in 1992. From 1994 to early 1999, he was a Staff Scientist and Team Leader at Tularik, Inc. (South San Francisco, USA). In 1999, Dr. Rothe joined DeveloGen AG (Göttingen, Germany) as Vice President, Research and Development and later served as its Chief Scientific Officer. In July 2001, he co-founded U3 Pharma AG (Munich, Germany) and assumed the roles of Managing Director and CSO. He was instrumental in the acquisition of U3 Pharma by Daiichi Sankyo in 2008. From 2009 to 2012 he served as CEO and Member of the Board of Directors of Igenica, Inc. (Burlingame, USA). Prior to joining IBA GmbH, he was CEO of ImmunoQure AG (Munich, Germany) and CEO and Delegate of the Board of Directors of ImmunoQure Research AG (Zurich, Switzerland). Dr. Rothe studied biochemistry at the University of Tübingen before receiving his Ph.D. from the University of Munich and being awarded the Otto-Hahn Medal of the Max-Planck-Society. He is the author of numerous scientific articles and international patents.

Dr. Joachim Bertram

CSO - Dr. Joachim Bertram

Managing Director, Chief Scientific Officer
Joachim Bertram received his Ph.D. in microbiology in the department of Prof. Gottschalk at the University of Goettingen. Then he moved to the department of hematology and oncology headed by Prof. Hiddemann where he has held a number of positions of increasing seniority in the biomedical profession. He conducted scientific and applied research on the use of antisense oligonucleotides and ribozymes in the field of proliferative diseases. In addition he focussed on mechanisms of drug resistance development and the use of nucleic acid based compounds for growth factor mimicry. In 1998, Joachim Bertram finished his "habilitation" in the medical faculty. He joined IBA GmbH in January 2000 and became CEO of IBA Biologics in 2001.

Dr. Herbert Stadler

Dr. Herbert Stadler

Head of the Advisory Board
Over the last two decades, Herbert Stadler has built a track record as one of Germany's most active biotech entrepreneurs. He has founded or co founded several companies including Biometra GmbH, Ribonetics GmbH, HepaVec AG, IBA GmbH and DeveloGen AG. Herbert Stadler is a neurochemist by training. He obtained his Ph.D. at the Freie University of Berlin, obtained his postdoctoral lecture qualification ("Habilitation") at the University of Göttingen and headed the Molecular Neurobiology Group at the Max-Planck Institute of Biophysical Chemistry in Göttingen. He currently serves on the supervisory boards of DeveloGen AG and IBA GmbH. 

Cell selection & expansion

Dr. Fabian Mohr

Protein Products & Assays

Dennis Karthaus

Protein Production

Dr. Christos Gouloudis

Marketing & Sales

Dr. Isabel Schuchardt
Director Product Management

Anna Färger
Director Marketing

General contact information

Phone +49 (0) 551 50672-0
Fax +49 (0) 551 50672-181
E-mail info@iba-lifesciences.com

Innovation Award 2015 – Pioneer work in developing rapid diagnostic tests
This year 101 participants applied for the 13th Innovation Prize of the county Göttingen. IBA was nominated together with the Fassisi GmbH for the joint project in the category “candidates with more than 20 employees”. Among the 29 nominees, the diagnostic test for veterinary diseases of IBA and Fassisi was choosen as one of the top five innovations.
Veteri-nost® is a prototype and represents a rapid and cost-effective device. It is based on IBA’s Strep-tag®/Strep-Tactin® technology that is used as standardized diagnostic tool. The analysis is similar to a pregnancy test. A test strip changes the color if disease related proteins are present.
For the measurement, blood or other body fluids are used to determine pathological changes.
Dr. Joachim Bertram, the managing director of IBA, states: “This technology sets a new benchmark for rapid diagnostic tests. The procedures can be applied to various antigens. Similar to a puzzle, one part of the system can easily be exchanged so that a different pathogen is detected. This is completely new and pioneering.”
A movie introducing our innovation is available on YouTube:
6th Foreign Trade Award of Lower Saxony

The Minister of Economics of Lower Saxony, Olaf Lies, granted the 6th Trade Award in the capital city Hanover. In the category small and medium-sized businesses IBA GmbH was nominated as one of the top five companies. This award appreciates the export-oriented German industry and honored innovative companies who have asserted themselves in the international export market.  Dr. Joachim Bertram and Dr. Thomas Schmidt, both managing directors of IBA, received the prize at the trade fair in Hanover on 15 April 2015 and felt much honored to be under the first ones of totally 69 companies applied for this award.

More information and the complete press release of the award ceremony here: http://www.mw.niedersachsen.de/aktuelles/presseinformationen/minister-olaf-lies-verleiht-auenwirtschaftspreis--132900.html

ISO 9001:2015 Quality Management Standard certification

Being the most recognized quality management standard in the world, ISO 9001:2015 is designed to help organizations to ensure that they meet the needs of customers and employees. It recognizes that the policies, practices and procedures of a company consistently result in high quality products and services which are provided to their customers.

Dr. Joachim Bertram, Managing Director at IBA, discusses receipt of the certificate: “Since 2004, IBA’s production and customer service fulfilled the high level of the ISO demands and standard procedures. However, gaining this accreditation now enables us to really demonstrate and highlight our high quality performance to our customers”.

IBA GmbH is dedicated to providing high quality tools for life science research and supports customers from early discovery to commercialization in industry and academia. The company offers solutions for the entire production chain of recombinant proteins, from oligonucleotide custom synthesis, cloning, transfection, protein expression and purification, to detection, immobilization and assays. We also deliver new tools for immunology research, including a growing line of tag-based reagents for cell isolation.

Innovation Award 2011 for the unique Streptamer® technology
In recognition of the innovative Streptamer® technology IBA was granted this local award.

For more information please watch the Streptamer® video (in German).